Thursday, September 19, 2019

Evidence underpinning approval of new cancer drugs raises questions

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, which indicates that treatment effects might have been exaggerated, concludes a new study.

from Latest Science News -- ScienceDaily https://ift.tt/31A1EwW
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Study finds untreated sleep apnea doubles Parkinson’s risk

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP users had much lowe...